Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9651161rdf:typepubmed:Citationlld:pubmed
pubmed-article:9651161lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:9651161lifeskim:mentionsumls-concept:C1511609lld:lifeskim
pubmed-article:9651161lifeskim:mentionsumls-concept:C0084253lld:lifeskim
pubmed-article:9651161pubmed:issue14lld:pubmed
pubmed-article:9651161pubmed:dateCreated1998-7-24lld:pubmed
pubmed-article:9651161pubmed:abstractTextThree carbocylic analogues of the potent cytidine deaminase inhibitor (CDA) zebularine [1-(beta-D-ribofuranosyl)-1, 2-dihydropyrimidin-2-one, 1a] were synthesized. The selected pseudosugar templates correspond, respectively, to the cyclopentenyl moiety of neplanocin A (compound 4), the cyclopentyl moiety of aristeromycin (compound 5), and a newly designed, rigid bicyclo[3.1. 0]hexane moiety (compound 6). These three carba-nucleoside versions of zebularine were fashioned to overcome the inherent instability of the parent drug. Each target compound was approached differently using either convergent or linear approaches. The immediate precursor to the cyclopentenyl analogue 4 was obtained by a Mitsunobu coupling of pseudosugar 7 with 2-hydroxypyrimidine. The cyclopentyl analogue 5 was linearly constructed from carbocyclic amine 17, and the final target 6 was similarly constructed from the carbobicyclic amine 27. Of the three target compounds, only 5 showed a significant level of inhibition against human CDA, but it was 16 times less potent than zebularine (Ki = 38 microM vs Ki(apparent) = 2.3 microM). Although these carbocyclic analogues appeared to be more stable than zebularine, replacement of the electronegative CO4' oxygen for the less electronegative carbon in 4-6 presumably reduces the capacity of the pyrimidin-2(1H)-one ring to form a covalent hydrate, a step considered crucial for the compound to function as a transition-state inhibitor of the enzyme.lld:pubmed
pubmed-article:9651161pubmed:languageenglld:pubmed
pubmed-article:9651161pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:citationSubsetIMlld:pubmed
pubmed-article:9651161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9651161pubmed:statusMEDLINElld:pubmed
pubmed-article:9651161pubmed:monthJullld:pubmed
pubmed-article:9651161pubmed:issn0022-2623lld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:CooneyD ADAlld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:McCormackJ...lld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:HauPPlld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:MarquezV EVElld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:JeongL SLSlld:pubmed
pubmed-article:9651161pubmed:authorpubmed-author:BuengerGGlld:pubmed
pubmed-article:9651161pubmed:issnTypePrintlld:pubmed
pubmed-article:9651161pubmed:day2lld:pubmed
pubmed-article:9651161pubmed:volume41lld:pubmed
pubmed-article:9651161pubmed:ownerNLMlld:pubmed
pubmed-article:9651161pubmed:authorsCompleteYlld:pubmed
pubmed-article:9651161pubmed:pagination2572-8lld:pubmed
pubmed-article:9651161pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:meshHeadingpubmed-meshheading:9651161-...lld:pubmed
pubmed-article:9651161pubmed:year1998lld:pubmed
pubmed-article:9651161pubmed:articleTitleCarbocyclic analogues of the potent cytidine deaminase inhibitor 1-(beta-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine).lld:pubmed
pubmed-article:9651161pubmed:affiliationLaboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.lld:pubmed
pubmed-article:9651161pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9651161pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9651161lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9651161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9651161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9651161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9651161lld:pubmed